Publications by authors named "Joseph M Gozgit"

Claim this Profile
P
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Joseph M Gozgit, Melissa M Vasbinder, Ryan P Abo, Kaiko Kunii, Kristy G Kuplast-Barr

Cancer Cell· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
Joseph M Gozgit, Tzu-Hsiu Chen, Youngchul Song, Scott Wardwell, Frank Wang

Oncotarget· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
Lindsay A Marek, Trista K Hinz, Anne von Mässenhausen, Kyle A Olszewski, Emily K Kleczko, Joseph M Gozgit

Mol Cancer Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.
Katerina D Fagan-Solis, Brian T Pentecost, Joseph M Gozgit, Brooke A Bentley, Sharon M Marconi

J Cell Physiol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Murry W Wynes, Trista K Hinz, Dexiang Gao, Michael Martini, Lindsay A Marek, Joseph M Gozgit

Clin Cancer Res· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
Neil P Shah, Moshe Talpaz, Michael W N Deininger, Michael J Mauro, Ian W Flinn, Joseph M Gozgit

Br J Haematol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Joseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, David Miller, Scott Wardwell

Cancer Chemother Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
Valentina De Falco, Preziosa Buonocore, Magesh Muthu, Liborio Torregrossa, Fulvio Basolo, Joseph M Gozgit

J Clin Endocrinol Metab· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers.
Casey M Turk, Katerina D Fagan-Solis, Kristin E Williams, Joseph M Gozgit, Sallie Smith-Schneider

Cancer Cell Int· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Joseph M Gozgit, Matthew J Wong, Lauren Moran, Scott Wardwell, Qurish K Mohemmad

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Joseph M Gozgit, Matthew J Wong, Scott Wardwell, Jeffrey W Tyner, Marc M Loriaux

Mol Cancer Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Michael Hedvat, Dennis Huszar, Andreas Herrmann, Joseph M Gozgit, Anne Schroeder

Cancer Cell· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.
Joseph M Gozgit, Geraldine Bebernitz, Pankaj Patil, Minwei Ye, Julie Parmentier

J Biol Chem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer.
Joseph M Gozgit, Brian T Pentecost, Sharon A Marconi, Christopher N Otis, Chuanyue Wu

Mol Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential action of polycyclic aromatic hydrocarbons on endogenous estrogen-responsive genes and on a transfected estrogen-responsive reporter in MCF-7 cells.
Joseph M Gozgit, Kathleen M Nestor, Michael J Fasco, Brian T Pentecost, Kathleen F Arcaro

Toxicol Appl Pharmacol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis